Evidence map›Paper›PMID 40104748›Full record

ArticleTranslational cancer research2025

The miR-155-5p/

Tao Yuan, Haiyan Liu, Fangfang Li, Qingyue Meng, Yajuan Wang, Mei Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tao YuanHospital Office, The No. 3 People's Hospital of Qingdao, Qingdao, China.
Haiyan LiuDepartment of Dermatology, The No. 8 People's Hospital of Qingdao, Qingdao, China.
Fangfang LiDepartment of Respiratory Medicine, The No. 8 People's Hospital of Qingdao, Qingdao, China.
Qingyue MengDepartment of Health Management Center, The No. 8 People's Hospital of Qingdao, Qingdao, China.
Yajuan WangDepartment of Gerontology, The No. 8 People's Hospital of Qingdao, Qingdao, China.
Mei YuanHealth Management Center, the Affiliated Hospital of Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) is a leading cause of cancer-related death. MicroRNAs (miRNAs or miRs) play a crucial role in the pathology of GC, including cell proliferation, invasion, and metastasis. In this study, genes targeted by miR-155-5p were predicted using bioinformatic tools. We found that the expression of miR-155-5p in GC cell lines differed relative to the expression of F-box protein 11 ( Methods: The luciferase reporter assay results showed that miR-155-5p bound directly to the three prime untranslated region (3'-UTR) of Results: We found that Conclusions: Overall, these results showed that miR-155-5p may serve as a tumor suppressor in GC and that the miR-155-5p/

Indexed as

FBXO11Gastric cancer (GC)mammalian target of rapamycin pathway (mTOR pathway)miR-155-5pproliferation

Identifiers

PMID40104748
PMCPMC11912068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.